(Reuters) – Regeneron Pharmaceuticals Inc and its partner Sanofi said on Friday they voluntarily withdrew their application with the U.S. health regulator for additional use of anti-cancer drug Libtayo as second-line treatment for patients with advanced cervical cancer.
(Reporting by Leroy Leo; Editing by Shinjini Ganguli)
